Difference between revisions of "Sanofi-Aventis Group"
(starting new page - management committee) |
(adding more details) |
||
| Line 1: | Line 1: | ||
| + | Sanofi-Aventis describes itself as 'one of the leading pharmaceutical companies worldwide and number 1 in Europe' <ref>[http://en.sanofi-aventis.com/Images/sanofi_ra06_en_tcm24-17381.pdf Sanofi-Aventis Annual report 2006] page 1. Accessed 30th November 2007.</ref> | ||
| + | They claim to be a 'socially responsible player in the healthcare sector' with a commitment to ensuring access 'for the most underprivileged populations to vaccines and medicines'<ref>[http://en.sanofi-aventis.com/Images/sanofi_ra06_en_tcm24-17381.pdf Sanofi-Aventis Annual report 2006] page 1. Accessed 30th November 2007.</ref> | ||
| + | |||
| + | However, they voice concern at the actions of countries who are engaged in trying to reduce the price of pharmaceutical products. Their Annual Report states that the development of generic varieties of medicines and vaccines and the actions of 'certain countries' who try to 'circumvent patent rights to allow their underprivileged populations to gain access to medicines' are 'unfavourable factors' facing the pharmaceutical industry. In the opening statements of their Annual Report, the Chairman and CEO stresses that ensuring intellectual property rights and patents are 'critical issues' facing Sanofi-Aventis both now and in the future. They go on to report how in 2006 they succeeded in imposing a 'preliminary injunction' effectively blocking any new deliveries of a generic version of Plavix into the market from August 2006 onwards <ref>[http://en.sanofi-aventis.com/Images/sanofi_ra06_en_tcm24-17381.pdf Sanofi-Aventis Annual report 2006] pages 5 & 20. Accessed 30th November 2007.</ref> | ||
| + | |||
| + | Plavix works by inhibiting blood clots in order to reduce the risk of strokes and heart attacks. It is distributed by: | ||
| + | Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership | ||
| + | Bridgewater, NJ 08807 <ref>[http://products.sanofi-aventis.us/plavix/plavix.html Plavix product details] Accessed 30th November 2007</ref> | ||
| + | |||
==Management Committee== | ==Management Committee== | ||
In their 2006 Annual Report, Sanofi-Aventis list their management committee as follows...<ref>[http://en.sanofi-aventis.com/Images/sanofi_ra06_en_tcm24-17381.pdf Sanofi-Aventis Annual report 2006] Accessed 30th November 2007.</ref> | In their 2006 Annual Report, Sanofi-Aventis list their management committee as follows...<ref>[http://en.sanofi-aventis.com/Images/sanofi_ra06_en_tcm24-17381.pdf Sanofi-Aventis Annual report 2006] Accessed 30th November 2007.</ref> | ||
| Line 24: | Line 33: | ||
The Annual Report continues by reporting that as of January 2007 [[Jean-Francois Dehecq]] takes on the role of Chairman of the Board of Directors. | The Annual Report continues by reporting that as of January 2007 [[Jean-Francois Dehecq]] takes on the role of Chairman of the Board of Directors. | ||
| + | |||
| + | Sanofi-Aventis report a | ||
| + | |||
| + | ==Affiliations== | ||
| + | Sanofi-Aventis claims to have strengthened its presence in the biotechnology area in 2006 through an agreement with [[Innogenetics]] and [[Inserm]] (through its affiliate [[Inserm Transfert]]) for a 2 year joint project in Alzheimer's disease. <ref>ibid</ref> | ||
| + | |||
| + | They also work in collaborative partnership with the [[Pediatric Dengue Fever Vaccine Initiative]] (PDVI), a programe of the [[International Vaccine Initiative]] financed by the [[Bill & Melinda Gates Foundation]]. <ref>[http://en.sanofi-aventis.com/Images/sanofi_ra06_en_tcm24-17381.pdf Sanofi-Aventis Annual report 2006] Page 18. Accessed 30th November 2007.</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 13:36, 30 November 2007
Sanofi-Aventis describes itself as 'one of the leading pharmaceutical companies worldwide and number 1 in Europe' [1] They claim to be a 'socially responsible player in the healthcare sector' with a commitment to ensuring access 'for the most underprivileged populations to vaccines and medicines'[2]
However, they voice concern at the actions of countries who are engaged in trying to reduce the price of pharmaceutical products. Their Annual Report states that the development of generic varieties of medicines and vaccines and the actions of 'certain countries' who try to 'circumvent patent rights to allow their underprivileged populations to gain access to medicines' are 'unfavourable factors' facing the pharmaceutical industry. In the opening statements of their Annual Report, the Chairman and CEO stresses that ensuring intellectual property rights and patents are 'critical issues' facing Sanofi-Aventis both now and in the future. They go on to report how in 2006 they succeeded in imposing a 'preliminary injunction' effectively blocking any new deliveries of a generic version of Plavix into the market from August 2006 onwards [3]
Plavix works by inhibiting blood clots in order to reduce the risk of strokes and heart attacks. It is distributed by: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership Bridgewater, NJ 08807 [4]
Management Committee
In their 2006 Annual Report, Sanofi-Aventis list their management committee as follows...[5]
- Gerard Le Fur- CEO
- Hanspeter Spek - Executive Vice President, Pharmaceutical Operations.
- Jean-Claude Leroy - Executive Vice President, Finance & Legal.
- Pierre Chancel - Senior Vice President, Global Marketing.
- Olivier Charmeil - Senior Vice President, Pharmaceutical Operations Asia/Pacific.
- Marc Cluzel - Senior Vice President, Scientific & Medical Operations.
- Laurence Debroux - Senior Vice President, Chief Financial Officer.
- Philippe Fauchet - Senior Vice President, Pharmaceutical Operations Japan.
- Belen Garijo - Senior Vice President, Phamaceutical Operations Europe (excluding France & Germany) & Canada.
- Gregory Irace - Senior Vice President, Phamaceutical Operations U.S.
- Michel Labie - Senior Vice President, Communications, Institutional & Professional Relations.
- Marie-Helene Laimay - Senior Vice President, Audit & Internal Control Assessment.
- Christian Lajoux - Senior Vice President, Phamaceutical Operations, France.
- Jean-Michel Levy - Senior Vice President, Business Development.
- Gilles Lhernould - Senior Vice President, Industrial Affairs.
- Karen Lineham - Senior Vice President, Legal Affairs & general Counsel.
- Heinz-Werner Meier - Senior Vice President, Pharmaceutical Operations Germany & Corporate Human Resources.
- Antoine Ortoli - Senior Vice President, Pharmaceutical Operations Intercontinental.
- Philippe Peyre - Senior Vice President, Corporate Affairs.
- David Williams - Senior Vice President, Vaccines.
The Annual Report continues by reporting that as of January 2007 Jean-Francois Dehecq takes on the role of Chairman of the Board of Directors.
Sanofi-Aventis report a
Affiliations
Sanofi-Aventis claims to have strengthened its presence in the biotechnology area in 2006 through an agreement with Innogenetics and Inserm (through its affiliate Inserm Transfert) for a 2 year joint project in Alzheimer's disease. [6]
They also work in collaborative partnership with the Pediatric Dengue Fever Vaccine Initiative (PDVI), a programe of the International Vaccine Initiative financed by the Bill & Melinda Gates Foundation. [7]
References
- ↑ Sanofi-Aventis Annual report 2006 page 1. Accessed 30th November 2007.
- ↑ Sanofi-Aventis Annual report 2006 page 1. Accessed 30th November 2007.
- ↑ Sanofi-Aventis Annual report 2006 pages 5 & 20. Accessed 30th November 2007.
- ↑ Plavix product details Accessed 30th November 2007
- ↑ Sanofi-Aventis Annual report 2006 Accessed 30th November 2007.
- ↑ ibid
- ↑ Sanofi-Aventis Annual report 2006 Page 18. Accessed 30th November 2007.
